Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 1:29 AM ET

Life Sciences Tools and Services

Company Overview of The Hamner Institutes for Health Sciences

Company Overview

The Hamner Institutes for Health Sciences provides research in environmental health sciences and chemical risk assessment. The company also provides translational research in biotechnology and pharmaceutical safety, metabolic disorders, diabetes, respiratory disease, oncology, and drug delivery/nanomedicine; and a gateway to establish research collaborations with the bio/pharmaceutical industry and countries in Europe and Asia, as well as acts as a catalyst to facilitate life sciences technology development among North Carolina universities. In addition, it offers human health assessment; center for genomic biology and bioinformatics, dose response modeling, and drug safety sciences; and tox...

6 Davis Drive

Research Triangle Park, NC 27709-2137

United States

Founded in 1974



Key Executives for The Hamner Institutes for Health Sciences

Chief Executive Officer, President and Director
Treasurer and Director
Secretary and Director
Division Director of Toxicology & Preclinical Studies
Director Division of Computational Biology & Program in Chemical Safety Sciences
Compensation as of Fiscal Year 2015.

The Hamner Institutes for Health Sciences Key Developments

The Hamner Institutes for Health Sciences and Cellular Dynamics Collaborate Announce Collaborative Agreement to Develop in Vitro Assays Using Human pluripotent stem Cell-Derived Hepatocytes

The Hamner Institutes for Health Sciences announced a collaborative agreement with Cellular Dynamics International to develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments that utilize CDI's human induced pluripotent stem (iPS) cell-derived hepatocytes. Current in vitro models of liver function employ immortalized cell lines, animal models and primary tissue isolates harvested from human cadavers. Each of these model systems presents limitations in functionality, reproducibility, translatability and availability. Human iPS cell-derived hepatocytes could provide a consistent, reproducible and limitless source of liver tissue that reflects native liver function and may offer significant improvement over existing in vitro models. CDI will provide iCell(R) Hepatocytes to The Hamner for use in an on-going program of research, referred to as 'Toxicity Testing in the 21st Century: Toxicity Pathways and Network Biology. This program employs several prototypical toxicity pathway case studies to develop human cell-based assays that map and model key cell signaling pathways in order to evaluate dose response. These assays, once validated with prototype chemicals, should enable toxicity testing and risk assessments based solely on in vitro test results, without progressing to toxicity studies in intact animals. These in vitro-based toxicity testing schemes will speed testing of both important compounds in commerce and new compounds coming into use. More rapid testing will also help assess the backlog of thousands of chemicals for which there is very limited toxicity test data. As these test technologies mature, they could also provide a means to speed drug discovery by providing assessments of safety far earlier in the drug development process. The Hamner toxicity pathway research program is a pre-competitive, multi-organization partnership designed to advance an integrated systems biology approach to toxicity testing research. Partners sponsoring the research include Agilent Technologies Inc., Illumina, Dow Chemical, Dow Corning Corporation, ExxonMobil, Unilever and CropLife America member companies. The Long-Range Research Initiative (LRI) of the American Chemistry Council supported earlier stages of this research. CDI will join this consortium and will collaborate with Hamner scientists on technical aspects of assay development.

Similar Private Companies By Industry

Company Name Region
Seahorse Bioscience, Inc. United States
Personalis, Inc. United States
Prosolia, Inc. United States
Aviana Molecular Technologies, LLC United States
PAREXEL Consulting Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Hamner Institutes for Health Sciences, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at